All In Biotech

Drug Trial Radar · NCT03664752

Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Participants With Acne Vulgaris

A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 585 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

585

Actual

Start

Dec 10, 2018

Primary completion

May 7, 2020

Study completion May 7, 2020

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Sep 10, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 9 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel

Conditions

  • Acne Vulgaris

Interventions

  • IDP-120 GelDrug

    IDP-120 Gel, once-daily application

  • IDP-120 Vehicle GelDrug

    IDP-120 Vehicle Gel, once-daily application

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Mean Lesion Counts at Week 12Time frame: Baseline to Week 12
  2. Percentage of Subjects Who Had at Least a 2-grade Reduction From Baseline at Week 12 in the Evaluator's Global Severity Score (EGSS) and Had an EGSS at Week 12 That Equated to "Clear" or "Almost Clear"Time frame: Baseline to Week 12

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Valeant Site 210

    Rogers, Arkansas

  • Valeant Site 201

    Manhattan Beach, California

  • Valeant Site 206

    San Diego, California

  • Valeant Site 218

    San Diego, California

  • Valeant Site 204

    Boynton Beach, Florida

  • Valeant Site 217

    Brandon, Florida

  • Valeant Site 202S

    Miami, Florida

  • Valeant Site 214

    Tampa, Florida

  • Valeant Site 222

    Snellville, Georgia

  • Valeant Site 215

    Boise, Idaho

  • Valeant Site 205

    Metairie, Louisiana

  • Valeant Site 216

    Clarkston, Michigan

  • Valeant Site 221

    Clinton Township, Michigan

  • Valeant Site 227

    Rochester, New York

  • Valeant Site 229

    Raleigh, North Carolina

  • Valeant Site 230

    Raleigh, North Carolina

  • Valeant Site 213

    San Antonio, Texas

  • Valeant Site 223

    Spokane, Washington

  • Valeant Site 219

    Waterloo, Ontario, Canada

  • Valeant Site 228

    Waterloo, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.